MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.58

+1.4%

Nov 5 12:44 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	3/14/2008 11:38:30 AM
	of 2240

Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody. Expert Opin Investig Drugs. 2008 Mar;17(3):371-85. Camacho LH. Department of Research Oncology Consultants PA, 920 Frostwood, Suite 780, Houston, TX 77024, USA. lcamacho@oncologyconsultants.com BACKGROUND: Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) is an activation-induced transmembrane receptor. Binding of CTLA4 to its natural ligands downregulates T-cell activation. Tremelimumab, a fully human IgG(2) monoclonal antibody binds CTLA4 and prevents ligand interaction resulting in enhanced cellular immunity. OBJECTIVE: To provide a comprehensive overview of the preclinical and clinical studies conducted during the development of tremelimumab. METHODS: Data with tremelimumab from all relevant preclinical studies and clinical trials completed at the time of publication and submitted to scientific meetings or published in peer-reviewed journals were collected and analysed. Salient clinical aspects observed during its early development were also included. RESULTS/CONCLUSIONS: CTLA4 blockade with tremelimumab at 15 mg/kg every 3 months has demonstrated substantial antitumor activity and an overall safe profile in patients with advanced melanoma. Phase III studies in melanoma and earlier stages of clinical development in colorectal, pancreatic, breast, and non-small cell lung carcinomas are ongoing.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next